View More Recent Stories

Jul 14, 2016 11:00AM Investigator-Sponsored Phase 2 Study Results Show pSivida’s Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
Jul 8, 2016 08:29AM pSivida Announces Poster and Oral Presentation on Controlled Release of Avastin® from Tethadur™ Biodegradable Matrix at the 2016 Controlled Release Society Annual Meeting
Jul 5, 2016 08:02AM pSivida (PSDV) Completes Two Preclinical Studies Utilizing Durasert Technology
Jul 5, 2016 08:00AM pSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
May 5, 2016 04:01PM pSivida Corp. Provides Company Update and Reports Third Quarter FY 2016 Results
May 4, 2016 08:00AM pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
May 2, 2016 07:36AM pSivida's (PSDV) Medidur Granted Orphan Drug Designation in Europe as Uveitis Treatment
May 2, 2016 07:30AM pSivida’s Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
Apr 27, 2016 09:00AM pSivida Corp. Announces Third Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Mar 24, 2016 09:00AM pSivida to Present at the Sidoti Spring 2016 Emerging Growth Convention
Mar 15, 2016 10:05AM pSivida (PSDV) Announces Positive Six-Month Safety Data for Medidur Phase 3 in PU
Mar 15, 2016 10:00AM Additional Favorable Six-Month Safety Results for pSivida's Medidur™ for Posterior Uveitis
Feb 8, 2016 04:01PM pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results
Feb 1, 2016 12:15PM pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Jan 28, 2016 10:30AM pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
Dec 28, 2015 07:16AM pSivida (PSDV) Plans to File EU Marketing Approval for Medidur
Dec 28, 2015 07:15AM pSivida Plans Medidur™ EU Marketing Approval Application Based on Single Phase 3 Clinical Trial
Dec 22, 2015 07:01AM pSivida (PSDV) Announces Medidur Phase 3 Met Primary Efficacy Endpoint
Dec 22, 2015 07:00AM pSivida's Medidur™ Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis (p Less Than 0.00000001)
Nov 5, 2015 04:05PM pSivida Corp. Provides Company Update and Reports First Quarter FY 2016 Results
Oct 30, 2015 08:00AM pSivida Corp Announces First Quarter FY 2016 Financial Results Release Date and Conference Call Information
Sep 28, 2015 07:15AM pSivida Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
Sep 14, 2015 08:00AM pSivida CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015
Sep 9, 2015 04:00PM pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2015 Results
Sep 3, 2015 08:00AM pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium
Sep 2, 2015 08:00AM pSivida Corp Announces Fourth Quarter and Fiscal Year 2015 Financial Results Release Date and Conference Call Information
Jul 21, 2015 08:45AM pSivida CEO to Speak at Controlled Release Society Annual Meeting Workshop in Edinburgh, Scotland, This Weekend
Jul 13, 2015 07:30AM pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis
Jul 7, 2015 11:15AM pSivida Announces Top-Line Results from Investigator-Sponsored Phase II Study of Medidur™ for Uveitis to Be Reported Next Week
Jun 24, 2015 07:15AM pSivida CEO to Present at ISOPT Clinical Meeting in Berlin in July 2015
May 19, 2015 07:35AM pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur™ for Posterior Uveitis
May 12, 2015 07:30AM pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company
May 8, 2015 07:30AM pSivida Corp. Reports Third Quarter FY 2015 Results
May 1, 2015 08:00AM pSivida Corp. Announces Third Quarter Fiscal Year 2015 Financial Results Release Date and Conference Call Information
Apr 14, 2015 08:07AM pSivida Corp. Reports ILUVIEN® for DME Approved in Poland
Mar 26, 2015 07:00AM pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis
Dec 5, 2013 12:19PM Streetinsider.com's Hot Lunchtime Reads 12/05: (RVBD) (JCP) (MSFT) (PVA)
View More Recent Stories